DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024

Core Viewpoint - Marinus Pharmaceuticals, Inc. has announced the cessation of clinical trial enrollment in the RAISE and RAISE II trials, which has led to significant stock price declines following the release of preliminary financial results and trial updates [1][6]. Company Overview - Marinus Pharmaceuticals is described as a commercial-stage pharmaceutical company focused on developing innovative therapeutics for seizure disorders, including rare genetic epilepsies and status epilepticus, with ZTALMY® (ganaxolone) being a key product [6]. Clinical Trials - The RAISE trial is a pivotal Phase 3 trial targeting refractory status epilepticus (RSE) patients. The company expressed disappointment that the trial did not meet early stopping criteria, indicating that the final outcome would only be determined after analyzing the full data set [6]. Stock Performance - Following the announcement on May 8, 2024, Marinus stock fell by $0.14 per share, or 8.91%, closing at $1.43 [7]. - On April 15, 2024, after the initial trial update, the stock price plummeted by $6.22 per share, or 82.7%, closing at $1.30, with an additional drop of $0.10, or 7.69%, to $1.20 the following day [9]. Legal Proceedings - A securities fraud class action lawsuit has been filed against Marinus on behalf of investors who purchased securities between March 17, 2021, and May 7, 2024, with a deadline of August 5, 2024, for potential lead plaintiffs to come forward [3][5].